Abstract
Sub-Saharan Africa is home to 89% of all young people living with HIV, a key population with specific challenges and needs. In-depth knowledge of service demands is needed to tailor and differentiate service delivery for this group. We evaluated HIV care preferences among young people living with HIV who were part of the PEBRA (Peer Educator Based Refill of ART) cluster-randomized trial.
The PEBRA trial evaluated a novel model of care at 20 health facilities in Lesotho, Southern Africa. In the PEBRA model, a peer educator regularly assessed participant preferences regarding antiretroviral therapy (ART) refill location, SMS notifications (for adherence, drug refill, viral load) and general care support options, and delivered services accordingly over a 12-month period. We present these preferences, their changes over time and how often it was not feasible to deliver them.
At enrolment, 41 of 123 (33.3%) chose ART refill outside the health facility, compared to 8 of 123 (6.5%) after 12 months. Among those selecting clinic-based ART refill, many collected ART during the peer educator led Saturday clinic club, 45 of 123 (36.5%) at the beginning and 55 of 123 (44.7%) at the end. SMS reminder for adherence and/or ART refill was chosen by 51 of 123 (41.5%) at enrolment and 54 of 123 (44.7%) at the last assessment. Support by the peer educator was popular at the beginning (110 of 123 (89.4%)) and lower but still high at the end (85 of 123 (69.1%)). 13 of 123 (10.6%) participants chose support by the nurse only at the first and 21 of 123 (17.1%) at the last assessment. The overarching trial was prospectively registered on ClinicalTrials.gov (NCT03969030).
Our longitudinal preference assessment among young people living with HIV showed a sustained interest in SMS notifications for adherence and refill visits as well as in additional support by a peer educator. ART refill outside the health facility was not as popular as expected; instead, medication pick-up at the facility, especially during Saturday clinic clubs, was favoured.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
It is registered with ClinicalTrials.gov (NCT03969030).
Clinical Protocols
https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-020-08535-6
Funding Statement
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol of the PEBRA trial was approved by the National Health Research and Ethics Committee of the Ministry of Health of Lesotho (118–2019 June 03, 2019) and the ethics committee in Switzerland (Ethikkommission Nordwest- und Zentralschweiz 2019-00480 June 14, 2019).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
E-mail addresses of the authors:
OS: olivia.a.seiler{at}gmail.com
MK: M.Kopo{at}solidarmed.ch
MKa: M.Kao{at}solidarmed.ch
TIL: t.Lejone{at}solidarmed.ch
NT: nadine.tschumi{at}swisstph.ch
TRG: tracy.glass{at}swisstph.ch
JAB: jennifer.brown{at}swisstph.ch
NDL: n.labhardt{at}unibas.ch
AA: alain.amstutz{at}unibas.ch
Data Availability
A key pseudo-anonymized individual participant dataset collected during the study, along with a data dictionary, will be made available at the time of publication through the data repository Zenodo with open access.